Stoke Therapeutics, Inc. (STOK) Q3 2025 10-Q Quarterly Report
Stoke Therapeutics, Inc. (STOK) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 4, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Stoke Therapeutics, Inc. Q3 2025 10-Q Analysis
Risk Factors
- • New clinical trial risk: Phase 3 EMPEROR study for zorevunersen initiated May 2025 with first patient dosed August 2025, increasing development and regulatory risk
- • Updated regulatory risk: June 2024 U.S. Supreme Court decision on Chevron doctrine may cause increased FDA challenges and regulatory delays
- • Most impactful compliance risk: FDA partial clinical hold removed but future holds possible; dosing limits imposed on chronic toxicology studies in 2022
- • Operational risk: Patient enrollment for rare diseases Dravet syndrome (1:15,600 incidence) and ADOA (1:30,000 incidence) may delay trials and revenue growth
- • Financial risk: Continued operating losses anticipated with no revenue; need additional funding to advance product development and commercialization
Get deeper insights on Stoke Therapeutics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.